Dr. Louis Sanfilippo, M.D. v. Dr. Timothy Brewerton, M.D. Lawsuit
 Alleging Fraud,  Negligence and Defamation

                        Exhibit 1      Exhibit 2      Exhibit 3      Exhibit  4      Exhibit 5   

                          Exhibit 6      Exhibit 7      Exhibit 8      Exhibit 9       Exhibit 10   

                          Exhibit 11     Exhibit 12    Exhibit 13    Exhibit 14     Exhibit 15  

                                                                         Exhibit 16 


​​​​                           2014-2017 News & Milestones​​​​


October 24, 2017 --  Shire and its Outside Counsel Haug Partners Implicated in Massive Double Standard, Hypocrisy Related to Supreme Court Case and Amicus Brief
August 24, 2017 -- Dr. Brewerton’s Parker Poe Lawyers Make Snappy "Reply" in Vyvanse-for-BED Fraud Lawsuit and Backpedal on Their Earlier Misstatements -- Have They Been Publicly Caught in a Lie?


August 11, 2017 -- Dr. Brewerton’s Parker Poe Lawyers Seek Dismissal of Fraud Lawsuit on Grounds that Dr. Sanfilippo Understood Brewerton’s IPR Declaration for Shire was Misrepresented and Therefore He Cannot Claim Fraud -- But Does this Help Dr. Brewerton, or Shire for that Matter?
August 4, 2017 -- Eating Disorder Survey Launching Nationwide
May 1, 2017 -- "Vyvanse for Binge Eating Disorder Patent" Lawsuit Centerpiece of Novel Anti-Fraud Platform
February 27, 2017 -- Vyvanse-for-BED Patent Lawsuit Takes Profile Deeper, to Shire’s Outside Counsel Frommer, Lawrence & Haug; Will There Be A Surprise Development in the Story? 


February 15, 2017 -- Dr. Louis Sanfilippo v. Dr. Timothy Brewerton “Vyvanse for BED Patent" Lawsuit Filed in Federal Court, Shire CEO Dr. Flemming Ornskov Informed. So Which Psychiatrist is Telling the Truth and Which Is Deceiving? You Can Be the Judge 


January 20, 2017 -- Louis Sanfilippo, M.D. v. Timothy Brewerton, M.D. Lawsuit Alleging Fraud, Negligence and Defamation Filed in U.S. District Court (South Carolina, Charleston Division


October 24, 2016  --  APS Holding Launches Web-Based Fraud Exposure Platform


​June 13, 2015 --  PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate
May 13, 2015 -- LCS Group Announces Exclusive License from Lucerne Biosciences to Commercialize '813 Patent and '249 Application through Shire's Marketing of Lisdexamfetamine Dimesylate for Binge Eating Disorder
January 30, 2015 -- United States Food & Drug Administration (FDA) Approves the Use of Lisdexamfetamine Dimesylate to Treat Binge Eating Disorder in Adults
December 26, 2014 -- LCS Therapeutics and Lucerne Biosciences to Commercialize '813 Patent for Lisdexamfetamine Dimesylate in the Treatment of Binge Eating Disorder


May 9, 2014 -- Shire Development LLC Files Inter Partes Review Petition Against LCS Group, LLC & U.S. Patent 8,318,813 in the Patent Trial & Appeal Board of the United States Patent & Trademark Office

Learn More

Contact Us Today

The Patent '813 Story*


    A Real-Life Story Unfolding in Real-Time 

      *U.S.  Patent No. 8,318,813 ("the '813 Patent") claims methods to treat Binge

            Eating Disorder With Lisdexamfetamine Dimesylate